Skip to main content
Atrás
Watch Compare

Orchestra BioMed Holdings, Inc.

Calidad de datos: 100%
OBIO
Nasdaq Manufacturing Measuring & Analyzing Instruments
$4.13
▼ $0.10 (-2.36%)
Cap. Mercado: 249.30 M
Precio
$4.26
Cap. Mercado
249.30 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Debt/Equity of 0.34 — conservative balance sheet
Negative free cash flow of -49.45 M
Capital efficient — spends only 1.46% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)1169.22%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-239.37%
Below sector avg (-53.47%)
ROIC-74.47%
Net Margin-157.40%
Op. Margin-154.73%

Seguridad

Debt / Equity
0.34
Above sector avg (0.30)
Current Ratio4.73
Interest CoverageN/A

Valoración

PE (TTM)
-4.73
Below sector avg (-1.48)
P/B Ratio5.70
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -4.7 -1.5
P/B 5.7 1.6
ROE % -239.4 -53.5
Net Margin % -157.4 -41.5
Rev Growth 5Y % — 1.8
D/E 0.3 0.3

Precio Objetivo de Analistas

7 analistas
Buy
Actual
$4.13
+200.9%
Objetivo
$12.43
$9.00
$12.00
$20.00
Pronóstico
P/E Futuro -2.43
EPS Futuro -$1.70
Ingresos Est. 887,250.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$1.70
-$2.04 – -$1.44
 887,250.0 5
FY2026 -$1.75
-$1.98 – -$1.53
 638,000.0 7

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.38 $0.26 +168.7%
Q32025 -$0.43 -$0.40 +6.7%
Q22025 -$0.51 -$0.50 +1.4%
Q12025 -$0.48 -$0.49 -1.7%

ETFs Holding This Stock

SHISX SHISX
0.02% weight
SHSCX SHSCX
0.02% weight
SHSAX SHSAX
0.02% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 1169.22% Revenue Growth (3Y) 248.30%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 33.48 M Net Income (TTM) -52.70 M
ROE -239.37% ROA -71.40%
Gross Margin N/A Operating Margin -154.73%
Net Margin -157.40% Free Cash Flow (TTM) -49.45 M
ROIC -74.47% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.34 Current Ratio 4.73
Interest Coverage N/A Asset Turnover 0.45
Working Capital 77.11 M Tangible Book Value 43.74 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -4.73 Forward P/E N/A
P/B Ratio 5.70 P/S Ratio 7.45
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19.84%
Market Cap 249.30 M Enterprise Value 222.29 M
Per Share
EPS (Diluted TTM) -1.11 Revenue / Share 0.57
FCF / Share -0.85 OCF / Share -0.84
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.46% FCF Conversion 93.84%
SBC-Adj. FCF -61.04 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Revenue 33.48 M 2.64 M 2.76 M — —
Net Income -52.70 M -61.02 M -49.12 M -2.74 M -173,542.0
EPS (Diluted) -1.11 -1.66 -1.48 -0.17 —
Gross Profit — — — — —
Operating Income -51.81 M -64.30 M -51.51 M -3.08 M —
EBITDA — — — — —
R&D Expenses 58.19 M 42.80 M 33.82 M — —
SG&A Expenses 26.91 M 23.93 M 20.26 M — —
D&A 327,000.0 308,000.0 287,000.0 — —
Interest Expense — 297,000.0 1.40 M — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 114.86 M 76.17 M 95.21 M 68.08 M 162.16 M
Total Liabilities 51.48 M 43.22 M 27.17 M 7.34 M 5.72 M
Shareholders' Equity 53.57 M 32.96 M 68.04 M -6.94 M 5.00 M
Total Debt 15.00 M 15.00 M — — —
Cash & Equivalents 34.69 M 22.26 M 30.56 M 175,161.0 2.03 M
Current Assets 107.91 M 69.17 M 89.11 M 299,079.0 2.15 M
Current Liabilities 16.74 M 16.21 M 11.21 M 1.74 M 118,956.0